WCLC 2022 | Real-world toxicities associated with lorlatinib in ALK+ NSCLC

So here at the World Lung Cancer Congress meeting in Vienna 2022, we presented our data on looking at real-world outcomes of toxicities for lorlatinib usage. We identified a small group of patients that have been treated with lorlatinib for ALK or ROS1. Indications and demonstrated that dyslipidemia was actually quite common, mostly low-grade occurring in about 90% of patients. About 60% of patients had peripheral edema of some cause and about 50% of patients had some sort of mood alteration identified, and 40% of patients had peripheral neuropathy. Now, when it comes to mood effects, mostly, these were low-grade effects that we had identified, but there were a couple of patients who had high-grade adverse events. Two patients had grade 4 depression, and one patient had grade 4 psychosis. These can be moderate or important mood effects and other adverse events with lorlatinib. But actually, these were able to be managed by dose reduction and supportive medication and in our experience, 45% of patients needed some form of dose reduction for their adverse events.